Abstract Title: Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling and Induces Mast Cell Apoptosis Poster Number: 541 Session Title: Novel Mechanisms of Mast Cells, Basophils and IgE ...
A new case report was published in Oncoscience's Volume 12 on February 4, 2025, titled “Breaking point: Systemic mastocytosis manifesting as severe osteoporosis.” ...
It's exactly seven years since Liverpool nailed their colours to the mast as a genuine contender for the Champions League.In ...
Chinese-owned telecommunications masts will be replaced on the roof of an 18-storey tower block. Bracknell Forest Council has ...
THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...
Q4 2024 Earnings Call Transcript February 13, 2025 Blueprint Medicines Corporation misses on earnings expectations. Reported ...
The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...
Blueprint Medicines Corporation ( NASDAQ: BPMC) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET ...
Asheville Area Chamber of Commerce CEO Kit Cramer opened the event with remarks on how Western ... The first panel included ...
Enanta Pharmaceuticals Inc. has discovered mast/stem cell growth factor receptor kit (KIT; c-KIT; CD117) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback